Once promising an alternative shot, Valneva's Covid-19 supply deal with Europe on verge of collapse
When French vaccine maker Valneva signed a purchase agreement with the European Commission in November, execs touted how the deal — under which it would supply 60 million doses of its inactivated, adjuvanted whole-virus Covid-19 vaccine — offered an alternative to the mRNA and adenovirus-based shots already out there.
But the whole deal may be in jeopardy now.
The EC first sent a notice of intent to terminate the purchase agreement back in May, as the regulatory review of Valneva’s vaccine stalled. Despite proposing a remediation plan, Valneva disclosed Friday that the latest discussions suggest the chances of reaching a revised deal are slim.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.